Figure 4.Kaplan–Meier curves of progression-free survival (PFS) of elderly patients (age ≥65 years) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). (A) All EGFR-TKIs; (B) gefitinib; (C) erlotinib; and (D) afatinib. Abbreviation: CI, confidence interval.
